chrX-65488953-T-C
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_001010888.4(ZC3H12B):āc.152T>Cā(p.Leu51Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00105 in 1,208,697 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 374 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Consequence
NM_001010888.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ZC3H12B | NM_001010888.4 | c.152T>C | p.Leu51Pro | missense_variant | 6/10 | ENST00000338957.5 | NP_001010888.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ZC3H12B | ENST00000338957.5 | c.152T>C | p.Leu51Pro | missense_variant | 6/10 | 1 | NM_001010888.4 | ENSP00000340839 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000612 AC: 68AN: 111126Hom.: 0 Cov.: 22 AF XY: 0.000510 AC XY: 17AN XY: 33340
GnomAD3 exomes AF: 0.000391 AC: 70AN: 179050Hom.: 0 AF XY: 0.000383 AC XY: 25AN XY: 65232
GnomAD4 exome AF: 0.00110 AC: 1207AN: 1097571Hom.: 0 Cov.: 31 AF XY: 0.000983 AC XY: 357AN XY: 363023
GnomAD4 genome AF: 0.000612 AC: 68AN: 111126Hom.: 0 Cov.: 22 AF XY: 0.000510 AC XY: 17AN XY: 33340
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 30, 2024 | The c.152T>C (p.L51P) alteration is located in exon 1 (coding exon 1) of the ZC3H12B gene. This alteration results from a T to C substitution at nucleotide position 152, causing the leucine (L) at amino acid position 51 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 17, 2020 | This sequence change replaces leucine with proline at codon 51 of the ZC3H12B protein (p.Leu51Pro). The leucine residue is weakly conserved and there is a moderate physicochemical difference between leucine and proline. This variant is present in population databases (rs199856860, ExAC 0.08%). This variant has not been reported in the literature in individuals with ZC3H12B-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at